Safety and effectiveness of hemoperfusion on the removal of uremic toxins in chronic kidney disease
10.16438/j.0513-4870.2020-1533
- VernacularTitle:血液灌流清除慢性肾病代表性毒素频度和效果的研究
- Author:
Meng-yao AN
1
,
2
;
Peng GE
3
;
Lei HU
3
;
Fei ZHONG
3
;
Bo-yu ZHOU
3
;
Chang-xiao LIU
1
,
2
,
4
Author Information
1. Department of Pharmaceutical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China
2. Tianjin Tiancheng New Drug Evaluation Research Co., Ltd., Tianjin 300301, China
3. Tianjin Tiancheng New Drug Evaluation Research Co., Ltd., Tianjin 300301, China
4. State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China
- Publication Type:Research Article
- Keywords:
chronic kidney disease;
beagle dog;
uremic toxin;
hemoperfusion;
blood purification
- From:
Acta Pharmaceutica Sinica
2020;55(12):2924-2933
- CountryChina
- Language:Chinese
-
Abstract:
The goal of the present study was to determine the effectiveness and safety of hemoperfusion (HP) in beagle dogs with chronic kidney disease (CKD). The experimental protocol was approved by the Institutional Animal Care and Use Committee of Tianjin Institute of Pharmaceutical Research New Drug Evaluation Research (IACUC2019071501). Twelve CKD model beagles were randomly divided into two groups: a low-frequency treatment group (n = 6) and a high-frequency treatment group (n = 6). The dogs in the high- and low-frequency groups received HP treatment every 3 days and once per week, respectively, for two treatments, with each session lasting 2 h. The test results showed that high-frequency HP treatment significantly decreased the accumulation of toxins in the CKD beagles. Hematology, coagulation function, electrolytes and liver function indicated that the HP treatment was safe. The body index effects were consistent between the low- and high-frequency treatment groups. Therefore, HP treatment once every 3 days was safe at the animal level. Multiple HP treatments every 3 days were more conducive than weekly treatments to the removal of uremic toxins with better prognosis and had no associated safety hazards.
